The OS win from HARMONi-2 de-risks ivonescimab's overall survival profile ahead of the November 14 PDUFA date for HARMONi. Traders should watch for presentation of the HARMONi-2 OS data at an upcoming medical conference and any FDA feedback on the BLA. Near-term upside hinges on FDA acceptance and label breadth for HARMONi, plus enrollment updates in HARMONi-7.
Drug in focus
SMMT drug pipeline →ivonescimab
◆ Mixed Named in this 8-K- Impact
- Phase
- Filed/PDUFA (BLA under FDA review); also multiple ongoing Phase 3 trials
- Time to market
- If approved, potential US launch in late 2026 or early 2027. Already approved in China (May 2024).
- Next catalyst
- None dated
What to watchThe November 14 PDUFA is the defining event. The HARMONi global trial showed statistically significant PFS but OS missed the pre-specified threshold, an unusual situation that creates binary risk on approval odds. Watch for an FDA Advisory Committee date (if scheduled) as a pre-decision signal. Also watch HARMONi-3 final PFS readout (2H 2026) as a secondary catalyst. The $500M June offering diluted existing holders but extended the cash runway, and the massive insider buying (~$100M from co-CEOs at ~$13.12) signals conviction at current levels.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 3 $17.13entry
- T+1 · 2mo ago +2.77%α +3.16% · $17.61
- T+5 · 2mo ago +2.45%α +3.60% · $17.55
- T+20 · 7w ago −1.28%α −0.17% · $16.91
- T+51 · todayOpen
- T+60 · in 13d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Partner Akeso announced statistically significant overall survival (OS) benefit for ivonescimab monotherapy vs pembrolizumab in the Phase III HARMONi-2 study (PD-L1-positive advanced NSCLC, China). HARMONi-2 already met its primary PFS endpoint (HR 0.51, p<0.0001) and received NMPA approval in China in April 2025. The OS win adds to ivonescimab's favorable risk/reward profile ahead of Summit's November 14, 2026 PDUFA date for HARMONi (EGFR-mutated NSCLC), while Summit's own HARMONi-7 global monotherapy study in PD-L1-high NSCLC is enrolling. This cross-filing positive readout supports Summit's ivonescimab franchise but remains a single-region China study, the pivotal confirmatory data for US/Europe approval will come from Summit's HARMONi trial.
Key Facts
- Phase III HARMONi-2 showed statistically significant OS benefit for ivonescimab vs pembrolizumab monotherapy in PD-L1-positive advanced NSCLC
- HARMONi-2 is a single-region China study by partner Akeso, data exclusively generated, managed, and analyzed by Akeso
- Ivonescimab already approved by China's NMPA (April 2025) based on the primary PFS endpoint (HR 0.51, 95% CI 0.38-0.69, p<0.0001)
- Summit's BLA for ivonescimab in EGFR-mutated NSCLC (HARMONi) was accepted by FDA in January 2026; PDUFA date is November 14, 2026
- Summit is enrolling HARMONi-7 (global Phase III, ivonescimab monotherapy vs pembrolizumab in PD-L1-high 1L NSCLC)
- Five Phase III ivonescimab trials have read out positive to date, all five with positive data
- No financial data (revenue, EPS, margins) was included in this filing
Financial Impact
No revenue or financial data reported; positive OS readout from partner study reduces regulatory risk for Summit's ivonescimab program and may improve commercial probability of success
Risk Factors
- HARMONi-2 is a single-region China study; results may not fully replicate in multinational pivotal trials
- Ivonescimab is not yet approved in Summit's license territories (US, Europe)
- No financial data filed, assessment relies on clinical trial trajectory, not reported revenue or profits
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001599298-26-000076 |
| Document: a2026_prx0902xharmoni-2o.htm | 0001599298-26-000076 |
| Document: 0001599298-26-000076-index-headers.html | 0001599298-26-000076 |
| Document: 0001599298-26-000076-index.html | 0001599298-26-000076 |
| Document: 0001599298-26-000076.txt | 0001599298-26-000076 |
Track record
23 reports on SMMT
6 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +23.34% at T+60 after the Jun 12, 2026 report. 8 of 11 went positive at some point.
Filters
- Nov 16, 2026today 8-K Bearish 7/10 Entry $11.43 Now $11.82 −3.41% settles Nov 17
- Nov 4, 202612d ago 8-K Neutral 3/10 Entry $14.19 to $16.33 Now $11.82 −16.70% ▲ +15.08% +14.77% vs SPY
- Nov 4, 202612d ago 8-K Neutral 6/10 Entry $14.19 to $16.33 Now $11.82 −16.70% ▲ +15.08% +14.77% vs SPY
- Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $16.17 to $14.19 Now $11.82 −26.90% ▼ −12.24% −7.84% vs SPY
- Oct 21, 202626d ago Press Release Neutral 5/10 Entry $15.83 to $15.55 Now $11.82 −25.33% ▼ −1.77% −0.59% vs SPY
- Oct 19, 202628d ago DEF 14A Neutral 5/10 Entry $15.57 to $16.09 Now $11.82 −24.08% ▲ +3.34% +3.00% vs SPY
- Sep 28, 20267w ago 8-K Bullish 8/10 Entry $16.39 to $16.91 Now $11.82 −27.88% ▲ +3.17% +3.38% vs SPY
- Sep 15, 20268w ago 8-K Bullish 7/10 Entry $17.40 to $17.54 Now $11.82 −32.07% ▲ +0.80% +0.48% vs SPY
- Sep 14, 20269w ago 8-K Bullish 7/10 Entry $18.42 to $17.40 Now $11.82 −35.83% ▼ −5.54% −5.08% vs SPY
- Sep 3, 202610w ago 8-K Bullish 6/10 Viewing Entry $17.13 to $17.61 Now $11.82 −31.00% ▲ +2.77% +3.16% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers